View source for Metabolic therapy with Sodium R lipoate plus hydroxycitrate

{{TreatmentInfo
|drug_name=Sodium R Lipoate and Hydroxycitrate (METABLOC)
|FDA_approval=No (Used in investigational metabolic therapy for brain tumors)
|used_for=Investigational use in brain tumor treatment, including primary and metastatic gliomas
|clinical_trial_phase=Early clinical evaluation in a small case series
|common_side_effects=Not specified in the provided information
|OS_with=Varies; one GBM patient had a significant tumor shrinkage, others showed extended progression-free survival, including one patient surviving 87 months post-diagnosis
|PFS_with=Majority of newly diagnosed patients without disease progression for periods extending to 2-3 years, and in one case, 87 months
|usefulness_rating=3
|notes=This metabolic therapy, combining sodium R lipoate and hydroxycitrate, has shown promising outcomes in a small French study involving glioma patients. The therapy aims to disrupt cancer metabolism, potentially extending survival and reducing tumor size in some patients. While preliminary results are encouraging, particularly for patients with newly diagnosed gliomas, the need for well-conducted, larger-scale trials is emphasized to firmly establish efficacy and safety.
|category=Over-the-Counter Drugs and Supplements
|links=
}}